 |
 |
Hi Bob, You raise very important questions. The Parkinson's Pipeline Project (www.pdpipeline.org) has been following the CEP 1347 trial and its halt. We believe the manner in which it was halted -- Cephalon comunicating the halt through a press release, before notifying the trial subjects or their doctors showed a lack of respect for the participants and for their health. The questions you bring up about cancer risks makes it even clearer that the trial participants should be given access to their medical records at the very least. Jean Burns who was a trial participant and is also a member of the Pipeline Project is compiling names and contact information for CEP 1347 participants. She said many of the participants want their medical records. There are too many unanswered questions. There were concerns about increasing risks of cancer, especially skin cancer from the start of this trial, and this should have been communicated to all of the participants. Exclusion criteria for participation that were listed on clinicaltrials.gov record included: “Have a history of prior malignancy (excluding basal or squamous cell cancer of the skin) within the previous 5 years Have an unresolved abnormal cancer screening test result before randomization” Have any history of malignant melanoma" Any CEP-1347 trial participants, please contact Jean Burns. Her email address is: [log in to unmask] Linda ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn